Tuon Felipe F, Koenig Fernando, Jacometto Daniel, Rocha Jaime L
Division of Infectious Diseases, Hospital de Clínicas da UFPR, Paraná, Curitiba, Brazil.
Rev Iberoam Micol. 2013 Jan 3;30(1):21-4. doi: 10.1016/j.riam.2012.09.003. Epub 2012 Sep 17.
Deoxycholate amphotericin B (DAB) is a nephrotoxic drug and the incidence of acute kidney injury (AKI) is high.
The aim of this study was to describe the incidence of AKI in patients under DAB therapy and determine risk factor to predict the AKI.
The data of this retrospective study included previously hospitalized patients treated with intravenous DAB for at least five days. Clinical and laboratorial data were evaluated and AKI was classified in stages using Acute Kidney Injury Network criteria. Univariated test followed by a multivariable analysis was performed to determine risk factor and Kaplan-Meier survival estimates were calculated to evaluate the role of AKI in the outcome.
One hundred six patients were included in the final analysis. AKI occurred in 51.9% and dialysis was necessary in 4.7%. The occurrence of AKI was not associated with any risk factor. The mortality of the patients was neither associated with AKI nor with dialysis. Other nephrotoxic drugs were not risk factors for AKI.
The incidence of AKI in patients using DAB is high and we cannot predict the chance of AKI using clinical or laboratorial data.
脱氧胆酸盐两性霉素B（DAB）是一种具有肾毒性的药物，急性肾损伤（AKI）的发生率很高。
本研究的目的是描述接受DAB治疗的患者中AKI的发生率，并确定预测AKI的危险因素。
这项回顾性研究的数据包括先前住院且接受静脉注射DAB治疗至少5天的患者。对临床和实验室数据进行评估，并使用急性肾损伤网络标准对AKI进行分期。先进行单变量检验，然后进行多变量分析以确定危险因素，并计算Kaplan-Meier生存估计值以评估AKI在预后中的作用。
106例患者纳入最终分析。AKI发生率为51.9%，4.7%的患者需要透析。AKI的发生与任何危险因素均无关联。患者的死亡率与AKI及透析均无关联。其他肾毒性药物不是AKI的危险因素。
使用DAB的患者中AKI的发生率很高，我们无法使用临床或实验室数据预测AKI的发生几率。
